Preclinical Data Support Thesis That Factor XIIa Inhibition Has the Potential to be an Effective Antithrombotic, Without Bleeding Side Effects
BURLINGTON, MA, USA I December 6, 2015 I Dyax Corp. (NASDAQ: DYAX) today announced a poster presentation describing preclinical data for DX-4012, the Company’s fully human monoclonal antibody to activated Factor XII (Factor XIIa), was presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 5-8, 2015 in Orlando, Florida.
“The poster presented at ASH this year describes how DX-4012 demonstrated anti-thrombotic activity in various animal models, without evidence of increased bleeding risk,” said Burt Adelman M.D., Chief Medical Officer and Executive Vice President of Research and Development at Dyax. “These data are a significant achievement for the Dyax research team and indicate that DX-4012, either as a monoclonal antibody or as a component of a bispecific antibody, shows potential as a novel antithrombotic therapy.”
A summary of data presented is below:
Title: Discovery and Characterization of a Highly Specific Antibody Inhibitor of Factor XIIa (FXIIa), and the Subsequent Generation of Factor XIIa/Plasma Kallikrein (PK) Bispecific Antibody
Date and time: Sunday, December 6, 2015 from 6:00 – 8:00pm ET
Abstract #: 83101
Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster II
Location: Hall A, Level 2
Summary: In this report, investigators describe the discovery and preclinical evaluation of DX-4012 as a highly selective and potent inhibitor of FXIIa. DX-4012 inhibits the proteolytic activity of FXIIa with an apparent Ki of ~15 pM, and does not inhibit closely related sequence homologs or other coagulation factors at concentrations up to 1 µM. When tested at 1 µM in human plasma, DX-4012 prolonged the activated partial thromboplastin time (aPTT) 3.4-fold, with no effect on the prothrombin time (PT). In a baboon arteriovenous shunt model of thrombosis, a single 10mg/kg intravenous infusion reduced platelet and fibrin deposition up to 192 hours after administration, demonstrating an antithrombotic effect with no increased risk of bleeding.
About DX-4012
Discovered using Dyax’s proprietary phage display technology platform, DX-4012 is a fully human monoclonal antibody inhibitor of FXIIa. Preclinical data indicate that DX-4012 shows potential as a novel antithrombotic therapy. Current areas of interest for this investigational product candidate are extracorporeal membrane oxygenation (ECMO), lupus anticoagulant syndrome and as a potential alternative treatment for patients who require prolonged antithrombotic therapy but cannot tolerate conventional anticoagulation.
About Dyax
Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.
Both DX-2930 and KALBITOR were identified using Dyax’s proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes two FDA approved products and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and royalties.
SOURCE: Dyax
Post Views: 154
Preclinical Data Support Thesis That Factor XIIa Inhibition Has the Potential to be an Effective Antithrombotic, Without Bleeding Side Effects
BURLINGTON, MA, USA I December 6, 2015 I Dyax Corp. (NASDAQ: DYAX) today announced a poster presentation describing preclinical data for DX-4012, the Company’s fully human monoclonal antibody to activated Factor XII (Factor XIIa), was presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 5-8, 2015 in Orlando, Florida.
“The poster presented at ASH this year describes how DX-4012 demonstrated anti-thrombotic activity in various animal models, without evidence of increased bleeding risk,” said Burt Adelman M.D., Chief Medical Officer and Executive Vice President of Research and Development at Dyax. “These data are a significant achievement for the Dyax research team and indicate that DX-4012, either as a monoclonal antibody or as a component of a bispecific antibody, shows potential as a novel antithrombotic therapy.”
A summary of data presented is below:
Title: Discovery and Characterization of a Highly Specific Antibody Inhibitor of Factor XIIa (FXIIa), and the Subsequent Generation of Factor XIIa/Plasma Kallikrein (PK) Bispecific Antibody
Date and time: Sunday, December 6, 2015 from 6:00 – 8:00pm ET
Abstract #: 83101
Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster II
Location: Hall A, Level 2
Summary: In this report, investigators describe the discovery and preclinical evaluation of DX-4012 as a highly selective and potent inhibitor of FXIIa. DX-4012 inhibits the proteolytic activity of FXIIa with an apparent Ki of ~15 pM, and does not inhibit closely related sequence homologs or other coagulation factors at concentrations up to 1 µM. When tested at 1 µM in human plasma, DX-4012 prolonged the activated partial thromboplastin time (aPTT) 3.4-fold, with no effect on the prothrombin time (PT). In a baboon arteriovenous shunt model of thrombosis, a single 10mg/kg intravenous infusion reduced platelet and fibrin deposition up to 192 hours after administration, demonstrating an antithrombotic effect with no increased risk of bleeding.
About DX-4012
Discovered using Dyax’s proprietary phage display technology platform, DX-4012 is a fully human monoclonal antibody inhibitor of FXIIa. Preclinical data indicate that DX-4012 shows potential as a novel antithrombotic therapy. Current areas of interest for this investigational product candidate are extracorporeal membrane oxygenation (ECMO), lupus anticoagulant syndrome and as a potential alternative treatment for patients who require prolonged antithrombotic therapy but cannot tolerate conventional anticoagulation.
About Dyax
Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.
Both DX-2930 and KALBITOR were identified using Dyax’s proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes two FDA approved products and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and royalties.
SOURCE: Dyax
Post Views: 154
